Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

被引：97

作者：

Day, Daphne ^{[1
,2
,3
]}

Hansen, Aaron R. ^{[1
,2
]}

机构：

[1] Princess Margaret Canc Ctr, Bras Drug Dev Program, Div Med Oncol & Hematol, 610 Univ Ave,Suite, Toronto, ON M5G 2M9, Canada

[2] Univ Toronto, Dept Med, Toronto, ON, Canada

[3] Ontario Inst Canc Res, OICR Res Fellow, 661 Univ Ave,Suite 510, Toronto, ON M5G 0A3, Canada

来源：

BIODRUGS | 2016年 / 30卷 / 06期

关键词：

PRETREATED ADVANCED MELANOMA; RESISTANT PROSTATE-CANCER; METASTATIC MELANOMA; OPEN-LABEL; DOUBLE-BLIND; PATIENTS PTS; PHASE-I; ANTI-CTLA-4; ANTIBODY; ANTI-PD-L1; NIVOLUMAB ANTI-PD-1;

D O I：

10.1007/s40259-016-0204-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown durable treatment responses in multiple tumor types by enhancing antitumor immunity. However, removal of self-tolerance can induce autoimmunity and produce a unique immune-driven toxicity profile, termed immune-related adverse events (irAEs). As ICIs gain approval for a growing number of indications, it is imperative clinicians increase their knowledge of and ability to manage irAEs. This review examines the etiology, presentation, kinetics, and treatment of irAEs and aims to provide practical guidance for clinicians.

引用

页码：571 / 584

页数：14

共 106 条

[1]

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma [J].

Albarel, Frederique ;

Gaudy, Caroline ;

Castinetti, Frederic ;

Carre, Tiphaine ;

Morange, Isabelle ;

Conte-Devolx, Bernard ;

Grob, Jean-Jacrues ;

Brue, Thierry .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) :195-204

[2]

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). [J].

Amin, Asim ;

Plimack, Elizabeth R. ;

Infante, Jeffrey R. ;

Ernstoff, Marc S. ;

Rini, Brian I. ;

McDermott, David F. ;

Knox, Jennifer J. ;

Pal, Sumanta Kumar ;

Voss, Martin Henner ;

Sharma, Padmanee ;

Kollmannsberger, Christian K. ;

Heng, Daniel Yick Chin ;

Spratlin, Jennifer L. ;

Shen, Yun ;

Kurland, John F. ;

Gagnier, Paul ;

Hammers, Hans J. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[3]

Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. [J].

Antonia, Scott Joseph ;

Goldberg, Sarah B. ;

Balmanoukian, Ani Sarkis ;

Sanborn, Rachel E. ;

Steele, Keith ;

Narwal, Rajesh ;

Robbins, Paul B. ;

Gu, Yu ;

Karakunnel, Joyson Joseph ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[4]

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). [J].

Antonia, Scott Joseph ;

Brahmer, Julie R. ;

Gettinger, Scott N. ;

Chow, Laura Quan Man ;

Juergens, Rosalyn A. ;

Shepherd, Frances A. ;

Laurie, Scott Andrew ;

Gerber, David E. ;

Goldman, Jonathan Wade ;

Shen, Yun ;

Harbison, Christopher ;

Alaparthy, Suresh ;

Chen, Allen C. ;

Borghaei, Hossein ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[5]

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Sileni, Vanna Chiarion ;

Pigozzo, Jacopo ;

Maio, Michele ;

Altomonte, Maresa ;

Del Vecchio, Michele ;

Di Guardo, Lorenza ;

Marchetti, Paolo ;

Ridolfi, Ruggero ;

Cognetti, Francesco ;

Testori, Alessandro ;

Bernengo, Maria Grazia ;

Guida, Michele ;

Marconcini, Riccardo ;

Mandala, Mario ;

Cimminiello, Carolina ;

Rinaldi, Gaetana ;

Aglietta, Massimo ;

Queirolo, Paola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[6]

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[7]

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[8]

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). [J].

Bendell, Johanna C. ;

Powderly, John D. ;

Lieu, Christopher Hanyoung ;

Eckhardt, S. Gail ;

Hurwitz, Herbert ;

Hochster, Howard S. ;

Murphy, Janet E. ;

Funke, Roel Peter ;

Rossi, Cheryl ;

Wallin, Jeffrey ;

Waterkamp, Daniel ;

Pishvaian, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

[9]

Bertrand, Anne ;

Kostine, Marie ;

Barnetche, Thomas ;

Truchetet, Marie-Elise ;

Schaeverbeke, Thierry .

BMC MEDICINE, 2015, 13

[10]

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

← 1 2 3 4 5 6 7 8 9 10 →